Search Results

NeuroSigma announced that the U.S. Food and Drug Administration cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder.

NeuroSigma, Inc. announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation, representing NeuroSigma’s first foreign subsidiary.

NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation Monarch eTNS System™ (Monarch 2.0).

NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced the commencement of a strategic digital marketing partnership with Data360, a leading provider of targeted, online marketing for the healthcare industry.

NeuroSigma, Inc. today announced the commercial launch of The Monarch eTNS System at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced that enrollment has commenced in two large, multicenter double-blind trials of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD).

NeuroSigma, Inc. announced that the Centers for Medicare & Medicaid Services has confirmed the durable medical equipment benefit category determination and two permanent Level II Healthcare Common Procedure Coding System codes for the Monarch eTNS® System, effective October 1, 2022, as part of the final coding decisions of its biannual update.

NeuroSigma, Inc., a bioelectronic medical device company, announced that KT Corporation has made a $5 million equity investment in NeuroSigma.

NeuroSigma, Inc., a bioelectronic medical device company, announced the promotion of Dr. Colin Kealey to President.